Description: Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Home Page: ultimovacs.com
Ullernchausséen 64
Oslo,
0379
Norway
Phone:
47 41 38 00 80
Officers
| Name | Title |
|---|---|
| Dr. Carlos de Sousa | Chief Exec. Officer |
| Mr. Hans Vassgård Eid | Chief Financial Officer |
| Ms. Ingunn Hagen Westgaard Ph.D. | Head of Research |
| Mr. Audun Tornes | Chief Technology Officer |
| Mr. Jens Egil Torbjorn Bjorheim M.D., Ph.D. | Chief Medical Officer |
| Mr. Oivind Foss Ph.D. | Head of Clinical Operations |
| Ms. Gudrun Troite Ph.D. | Head of Project Coordination |
| Mr. Antonius Berkien | Chief Bus. Officer |
| Prof. Gustav Gaudernack Ph.D. | Chief Scientific Officer |
| Ms. Anne H. Worsoe | Head of Investor Relations & Communication |
Exchange: OL
Country: NO
Currency: Norwegian Krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.4418 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 23 |